Renal insufficiency is a challenging clinical problem in patients with multiple myeloma. The standard therapy has been plasma exchange, which reduces serum light chain levels while chemotherapy reduces the number of light chain-secreting malignant plasma cells. In this issue, Clark and colleagues' study challenges this widely held standard of patient management.
|Original language||English (US)|
|Number of pages||3|
|Journal||Annals of internal medicine|
|State||Published - Dec 6 2005|
ASJC Scopus subject areas
- Internal Medicine